Optogenetics: the discovery that has won the Nobel Prize

The 2026 Nobel Prize in Physiology or Medicine has been awarded to biophysicists Peter Hegemann and Georg Nagel and neuroscientist Karl Deisseroth for the development of optogenetics, a revolutionary technology that uses photosensitive proteins derived from a single-celled alga as “molecular switches” to activate or inhibit neurons with pulses of light. What began as basic biological research into how the alga Chlamydomonas reinhardtii orients itself towards light has evolved into a groundbreaking tool for modern neuroscience that is capable of controlling brain circuits with high precision and opening new horizons in our understanding of the brain and its disorders.

The 2026 Nobel Prize in Physiology or Medicine has been awarded to German biophysicists Peter Hegemann (b. 1954) and Georg Nagel (b. 1953) and American physician Karl Deisseroth (b. 1971) for their discoveries on light-activated ion channels, which paved the way for the development of optogenetics. According to the Nobel Committee, this technique enables individual neurons in a living brain to be activated or inhibited. In other words, it acts as a kind of molecular switch for nerve cells, allowing researchers to activate (turn on) or deactivate (turn off) specific neural circuits in the brain using light. The award also recognizes the importance of the research process that led to this remarkable discovery.

A surprising finding: an alga that detects light

It all began in the early 1990s, when Peter Hegemann, a researcher at the Max Planck Institute for Biochemistry in Martinsried (Germany), observed unexpected behavior in a unicellular green alga of the species Chlamydomonas reinhardtii. When a culture of these algae in an aqueous medium was exposed to light, the organisms responded by moving towards it. This movement is facilitated by the two long flagella found on this chlorophyte, while light is detected using a tiny orange dot on the cell surface, a kind of eyespot.

Hegemann hypothesized that this spot enabled the organism to rapidly detect, respond, and orient itself towards the light source. This response is related to the movement of ions between the inside of the cell and the aqueous medium surrounding it. Ion channels—formed by proteins present in the eyespot region—open when they receive the light stimulus, allowing ions to flow across the cell membrane. This movement of charged particles generates an electrical signal that triggers the organism’s response and helps activate its flagella.

To study this phenomenon, Hegemann used microelectrodes to measure the electrical signals generated in the algae when illuminating the eyespot. He observed that the response occurred just half a millisecond after the light reached the eyespot, and that it was accompanied by an electrical impulse. The speed of the response was extraordinary: it was 20 times greater than the response associated with the flow of charged ions generated by the electrical signal in the human eye.^[2]

Hegemann proposed that a photosensitive protein called “rhodopsin”, found in the eyespot, played a fundamental role in generating the electrical signal that enabled the alga to respond to light. Nevertheless, it would be several years before the genes encoding these proteins were identified, a breakthrough that came when Japanese researchers published the alga’s genome.^[3]

Building on this knowledge, Georg Nagel, a researcher at the Max Planck Institute for Biophysics in Frankfurt, partnered with Hegemann to identify and characterize two proteins that they called “channelrhodopsins”. By synthesizing complementary DNA (cDNA), i.e., DNA obtained from RNA, they identified two genes that encode receptor proteins involved in phototaxis of the alga Chlamydomonas reinhardtii. Phototaxis is the movement of an organism in response to light, whereby it can move towards (positive phototaxis) or away from it (negative phototaxis).

Nagel and Hegemann designed an experiment that allowed them to isolate and characterize both proteins. Using genetic engineering techniques, they injected the two candidate Chlamydomonas genes into frog oocytes, which began producing the proteins and localizing them on the cell surface. They found that the proteins effectively function as ion channels that open when exposed to light, generating an electrical signal. The proteins were named channelrhodopsin-1 and channelrhodopsin-2.

However, the most extraordinary part was yet to come. Channelrhodopsins can cause other cells that do not normally respond to light in this way to become light-sensitive. The researchers introduced the gene for channelrhodopsin-2 into human embryonic kidney cells and hamster kidney cells, and found that the cells became light-sensitive and produced an electrical signal when illuminated.^[4]

Hegemann and Nagel realized that they had made a revolutionary discovery and suggested that channelrhodopsin-2 could become a powerful tool for generating electrical impulses in cells using light. A protein that had evolved in an alga to respond to light stimuli could now be used to control the activity of other cells.

The birth of optogenetics. Deisseroth and the leap to the brain

Unbeknownst to anyone at the time, the research into the behavior of an alga had just provided the “switch” that neuroscience had been waiting for to control neuronal activity. Young American neuroscientist Karl Deisseroth from Stanford University in California took up the baton, translating this concept to the study of the nervous system. His key contribution was applying Hegemann and Nagel’s discoveries to neurons using light-sensitive proteins to activate or inhibit them. And so, “optogenetics” was born.

For decades, neuroscientists had made great strides in understanding brain structure and neural activity through studies with electrodes and electrical stimulation techniques. However, a fundamental question remained: how could specific types of neurons be activated or inhibited without altering the activity of other cells at the same time?

Answering this question would allow researchers to explore fundamental questions about brain function, including the mechanisms involved in memory and information storage, reward systems, emotions, movement, and sleep. It would also help identify the circuits involved in behavior and in different neurological and psychiatric diseases.

Optogenetics offered a new way to address that challenge by turning light into a tool for controlling nerve cells with extraordinary precision. Experimental control of neural circuits opened up new avenues of research into brain function.

One of the major contributions of this technique is that it allows scientists to study which neurons are involved in certain brain functions and, above all, to experimentally determine what happens when a specific group of neurons is activated or silenced. To that end, Deisseroth and his collaborators introduced the genes that encode photosensitive proteins into the neurons of animal models, showing that they could control their activity using light. In this way, the protein discovered in the alga became a light-controlled “switch” for nerve cells. ^[5]

Genetic engineering techniques would, of course, be used to introduce the rhodopsin genes into the neurons in the animals’ brains. Experiments performed in living brains (in vivo) may require the use of invasive devices, such as optical fibers implanted in brain tissue that allow light to be delivered to the selected region.

Schematically, optogenetics requires four steps:

Choose a photosensitive protein. For example, channelrhodopsin-2. There are different proteins of this type: some allow neurons to be activated, while others are used to reduce or shut down their activity.
Introduce the corresponding gene into the selected neurons. Genetic engineering tools are used for this, including gene transfer or transgenesis techniques.
Deliver the light to the brain region under study. Systems capable of illuminating the selected cells are required, for example using optical fibers or other suitable devices.
Measure and control neural activity. Systems are needed to record the electrical activity of the cells and analyze how it changes when light activates the photosensitive proteins and alters the ion flow across the membrane.

In short, optogenetics uses light to control neurons genetically modified to express photosensitive proteins. The most important feature of this new technology is the ability to conduct causal experiments: what happens if I activate these neurons? Does a particular behavior emerge? And if I inhibit them, does it disappear or change? The first experiments were carried out on laboratory animals, including the fruit fly Drosophila melanogaster, rats, and mice.^[6] These studies demonstrated that the selective manipulation of certain groups of neurons could produce observable changes in behavior and other functions of the organism.

Reasons for the Nobel Prize

For the Nobel Assembly at Karolinska Institute in Stockholm, the merit of the research recognized by the 2026 Nobel Prize in Physiology or Medicine lies not only in the development of a new technology, but in the chain of discoveries that led from basic biological research to a revolutionary tool for neuroscience, with possible future implications for biomedical research and medicine.

The Nobel committee itself presents the story as a journey from research on algae to advanced experiments in neuroscience, highlighting the importance of basic research and unexpected connections between disciplines.

The contributions of the three researchers can be summarized as follows:

Optogenetics has enabled a major leap forward in neuroscience: the transition from observing the brain to experimentally manipulating it. This technique is on the verge of radically transforming our understanding of how the human brain works, and is expected to provide hitherto inaccessible information on how the nervous system interacts with various cells in other parts of the body, including the heart, muscles, and digestive system. It may also help address some of the big questions in neuroscience: How can an organ like the human brain, which weighs just 1.3 kilograms, harbor childhood memories, daydreams, and creativity? Where do feelings such as joy, love, and jealousy come from? How are the heart rate, breathing rate, and sleep cycle regulated? What processes go wrong in the different neurodegenerative diseases?

Limits and ethical challenges

This technology poses significant bioethical, clinical, and regulatory challenges, especially as it transitions from animal models to human studies.

Numerous difficulties persist, both from an experimental point of view and in potential medical applications. Among the issues that need to be resolved are the following: How do we translate findings from animal models to humans? How can the genes be introduced into the right cells without affecting others? How can light be delivered to deep brain regions? What long-term effects might the introduced proteins have on human neurons?

It is essential to exercise caution and distinguish between the possibilities currently offered by the technique and expectations for its future applications. Optogenetics has opened up new possibilities for investigating neurological diseases and improving our understanding of the mechanisms involved in psychiatric and neurological disorders—such as depression, anxiety, schizophrenia, Alzheimer’s disease, and Parkinson’s disease—and may also help us to gain insight into their causes and, in some areas, develop therapeutic strategies. Researchers are even considering its use in restoring vision, among other ophthalmologic applications. Nonetheless, it is important to recognize that the current capabilities of optogenetics as an experimental tool are still far from its application as a clinical treatment. We must avoid the sensationalist claim that the Nobel Prize will cure brain diseases. The path from experimental breakthrough to a safe and effective treatment requires numerous studies and clinical trials.

Priority issues also include safety concerns, given the invasive nature of the technique. Further preclinical trials in animal models are needed to determine whether the introduction of channelrhodopsins by invasive processes, such as intracranial injections into nervous tissue, can be carried out without risk to life or health. Research is also needed into how to activate these proteins with light at wavelengths long enough to penetrate tissues and, if technically feasible, facilitate stimulation without having to directly access the brain. This objective continues to present significant technical challenges.

It could be argued that, as far as the genetic modification introduced into neurons is concerned, it does not differ from somatic gene therapy techniques. However, in the case of optogenetics, the channelrhodopsin introduced is not therapeutic in itself; rather, it provides a tool for therapy by endowing neurons with the ability to be controlled using light. Once a patient’s neurons express channelrhodopsin, light could be used to manipulate their activity against their will (similar to what happens with so-called chemical submission) or to cause harmful cognitive or motor effects. Like almost all recent biotechnological innovations, optogenetics thus becomes a technology that can be used for good or evil. This activity needs to be regulated to minimize the risks of misuse while maximizing the potential benefits of its exclusively clinical applications.

It is also necessary to address the ethical issues that may arise as we acquire the ability to manipulate brain circuits involved in emotions or behavior. It is important to bear in mind that this is a technology that requires invasive procedures and that acts on the brain and nervous system, structures that are central to personal identity, autonomy, and mental life.^[7]

One particular concern is the application of optogenetics in patients with neurodegenerative diseases that impair their ability to sign an informed consent form. In these cases, patient protection should be at the heart of any research proposal or clinical application.

There is even the risk of this technology being deployed in disruptive transhumanist or post-humanist projects or, combined with artificial intelligence, using neural recordings without the knowledge or consent of individuals and in violation of their right to mental privacy.

Another aspect to take into account—both when selecting volunteers for potential clinical trials and once optogenetics has proven successful in patients with certain neurodegenerative diseases—is the principle of equity. Given the nature and cost requirements of this technology, it is important to consider the challenges of its general implementation in public healthcare systems.

In conclusion, optogenetics offers the possibility of manipulating the activity of neural circuits with high precision, and has generated a growing interest in harnessing this potential to treat a wide range of neurological and psychiatric disorders. To realize this potential, it is essential to identify and address the safety issues, evaluate the ethical concerns associated with the initial clinical trials, and adopt this technology exclusively for health-related purposes, under stringent regulations that safeguard human dignity and human rights.

Regardless, this represents a major milestone. A seemingly simple question—how does a single-celled organism know where light is?—has ultimately provided a tool to answer one of the great questions of science: how the brain works.